INCY - Incyte Non-GAAP EPS of $0.55 misses by $0.14 revenue of $733.24M misses by $20.3M; reaffirms FY22 guidance

Incyte press release (NASDAQ:INCY): Q1 Non-GAAP EPS of $0.55 misses by $0.14. Revenue of $733.24M (+21.3% Y/Y) misses by $20.3M. The Company has reaffirmed its full year 2022 financial guidance:  Jakafi guidance range of $2.33 to $2.4 billion for 2022 (prior $2.3 - $2.4 billion). The company expects other Hematology/Oncology net product revenue of $210M-$240M The company expects Non-GAAP R&D expenses of $1.42B-$1.46B The company expects Non-GAAP SG&A expenses of $880M-$925M.

For further details see:

Incyte Non-GAAP EPS of $0.55 misses by $0.14, revenue of $733.24M misses by $20.3M; reaffirms FY22 guidance